scholarly journals An unusual clonal chromosome abnormality der(17)t(11;17)(q24;p13)inv(11)(q13;q23) in a patient with chronic lymphocytic leukemia

2021 ◽  
Vol 5 (2) ◽  
pp. 028-031
Author(s):  
Monti Valentina ◽  
Serpenti Fabio ◽  
Farina Lucia ◽  
Moiraghi Maria Luisa ◽  
Testi Maria Adele ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
B Lymphocytes ◽  
Clinical Presentation ◽  
Chromosome Abnormality ◽  
Lymphocytic Leukemia ◽  
Response To Treatment

Chronic Lymphocytic Leukemia (CLL) is a common clonal neoplasm of small, mature B-lymphocytes. CLL is a heterogeneous disease with different clinical presentation, response to treatment and survival.

scholarly journals Functional heterogeneity of B-CLL lymphocytes: dissociated responsiveness to growth factors and distinct requirements for a first activation signal

Blood ◽  
1987 ◽  
Vol 70 (4) ◽  
pp. 1105-1110
Author(s):  
S Karray ◽  
H Merle-Beral ◽  
A Vazquez ◽  
JP Gerard ◽  
P Debre ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Growth Factors ◽  
Growth Factor ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
B Lymphocytes ◽  
Lymphocytic Leukemia ◽  
Functional Heterogeneity ◽  
B Cell Growth Factor ◽  
Directed Growth

We studied the effects of B cell directed growth factors on B lymphocytes from 11 patients with chronic lymphocytic leukemia (B-CLL). B-CLL lymphocytes were costimulated with anti-mu antibody (Ab) and with three growth factor preparations: recombinant IL2, B cell growth factor (BCGF) (20 kiloDalton (kD) BCGF) and a high molecular weight BCGF (50 kD BCGF). IL2 was the more active factor (in six of 11 patients). The effect of IL2 was dependent on a costimulation with anti-mu Ab or occurred independently of anti-mu Ab, according to the patients. This pattern of reactivity did not correlate with the presence or absence of the IL2 receptor (IL2-R) molecule on fresh B-CLL lymphocytes. Five patients responded to the 20 kD BCGF. Although four of them were also strong responders to IL2, one strongly responded to the 20 kD BCGF and did not respond to IL2. Only one patient responded to the 50 kD BCGF. When an anti-IL2-R Ab was introduced into the culture, only the responsiveness to IL2 was abolished: thus both 20 kD and 50 kD BCGFs activate B-CLL lymphocytes independently of the IL2-R. These results show that several B cell directed growth factors can act independently to support the proliferation of B-CLL lymphocytes.

scholarly journals Characterization of the phytohemagglutinin-induced proliferating lymphocyte subpopulations in chronic lymphocytic leukemia patients using a clonogenic agar technique and monoclonal antibodies

Blood ◽  
1981 ◽  
Vol 58 (5) ◽  
pp. 1053-1055 ◽  
Author(s):  
S Davis
Keyword(s):  
T Cells ◽  
Monoclonal Antibodies ◽  
Chronic Lymphocytic Leukemia ◽  
B Lymphocytes ◽  
Peripheral Blood Lymphocytes ◽  
Lymphocytic Leukemia ◽  
Helper T Cells ◽  
Suppressor T Lymphocytes ◽  
Pha Stimulation

Abstract Peripheral blood lymphocytes from normal donors and patients with chronic lymphocytic leukemia, B-cell type, were purified into T, helper T, and suppressor T lymphocytes by fluorescence-activated cell sorting using OKT3, OKT4, and OKT8 monoclonal antibodies. The maximum response of the purified subpopulations to stimulation by phytohemagglutinin (PHA) was determined by measuring the production of colonies when the stimulated cells were grown on agar. The helper T cells in normal and CLL patients were the most responsive to PHA stimulation, although the responsiveness of helper T cells to PHA was decreased in CLL. Purified CLL B cells responded minimally to PHA stimulation, but normal B lymphocytes did not. The abnormal response of CLL lymphocytes to PHA appears to be due abnormal helper T cells, and, to a smaller extent, to the ability of CLL B lymphocytes to respond.

scholarly journals Dissecting CLL through high-dimensional single-cell technologies

Blood ◽  
2019 ◽  
Vol 133 (13) ◽  
pp. 1446-1456
Author(s):  
Satyen H. Gohil ◽  
Catherine J. Wu
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Single Cell ◽  
Cancer Cells ◽  
Lymphocytic Leukemia ◽  
Response To Treatment ◽  
High Dimensional ◽  
Single Cell Level ◽  
Disease Course ◽  
Cell Level ◽  
New Techniques

Abstract We now have the potential to undertake detailed analysis of the inner workings of thousands of cancer cells, one cell at a time, through the emergence of a range of techniques that probe the genome, transcriptome, and proteome combined with the development of bioinformatics pipelines that enable their interpretation. This provides an unprecedented opportunity to better understand the heterogeneity of chronic lymphocytic leukemia and how mutations, activation states, and protein expression at the single-cell level have an impact on disease course, response to treatment, and outcomes. Herein, we review the emerging application of these new techniques to chronic lymphocytic leukemia and examine the insights already attained through this transformative technology.

scholarly journals Clinical presentation and hematological profile among young and old chronic lymphocytic leukemia patients in Sudan

2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Ameen Abdulaziz Basabaeen ◽  
Enaam Abdelrhman Abdelgader ◽  
Ebtihal Ahmed Babekir ◽  
Nada Hassan Eltayeb ◽  
Osama Ali Altayeb ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Clinical Presentation ◽  
Lymphocytic Leukemia ◽  
Hematological Profile

scholarly journals Lactic dehydrogenase in normal and leukemia lymphocyte subpopulations: evidence for the presence of abnormal T cells and B cells in chronic lymphocytic leukemia

Blood ◽  
1981 ◽  
Vol 57 (2) ◽  
pp. 324-327 ◽  
Author(s):  
P Rambotti ◽  
S Davis
Keyword(s):  
T Cells ◽  
B Cells ◽  
Chronic Lymphocytic Leukemia ◽  
T Lymphocytes ◽  
B Lymphocytes ◽  
Lactic Dehydrogenase ◽  
Isozyme Pattern ◽  
Lymphocyte Subpopulations ◽  
Lymphocytic Leukemia ◽  
Ldh Activity

Abstract Lactic dehydrogenase (LDH) was quantitated and the isozyme pattern studied in lymphocyte subpopulations from normal people and patients with chronic lymphocytic leukemia (CLL). Normal T lymphocytes differed from normal B lymphocytes in having greater total LDH activity (597.2 versus 252.1). Total LDH activity in CLL T cells (347.1) was lower than normal T cells., but not significantly different than normal B cells. Total LDH activity in CLL B cells (124.6) was lower then normal B cells and normal T cells. The isozyme pattern of normal T lymphocytes showed a higher activity in the LDH-1 band (26.7% versus 5.4%) but showed a lower activity in LDH-5 band (4.3% versus 16.3%) compared to normal B cells. Chronic lymphocytic leukemia T cells could be distinguished from CLL B cells by a high LDH-5 band (22.3% versus 7.6%) and from normal T cells by a high LDH-5 band (22.3% versus 4.3%) and a low LDH-1 band (7.3% versus 26.7%). CLL B cells could be distinguished from normal B cells by a low LDH-5 band (7.6% versus 16.3%). Thus, the LDH isozyme pattern distinguishes normal T lymphocytes from normal B lymphocytes, and normal T and B lymphocytes from CLL T and B lymphocytes.

scholarly journals Spurious E rosette formation in B cell chronic lymphocytic leukemia due to monoclonal anti-sheep RBC antibody

Blood ◽  
1985 ◽  
Vol 65 (2) ◽  
pp. 270-274 ◽  
Author(s):  
LE Mills ◽  
JF O'Donnell ◽  
PM Guyre ◽  
PJ LeMarbre ◽  
JD Miller ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
B Lymphocytes ◽  
Lymphocytic Leukemia ◽  
Rosette Formation ◽  
Surface Markers ◽  
Simultaneous Presence ◽  
Surface Immunoglobulin ◽  
Monospecific Antisera ◽  
Cell Chronic Lymphocytic Leukemia

Abstract The apparent simultaneous presence of surface markers characteristic of both B and T cells is a phenomenon being described with increasing frequency in patients with chronic lymphocytic leukemia (CLL). We describe a patient with CLL whose B lymphocytes possessed surface immunoglobulin reactive with neuraminidase-treated sheep erythrocytes (SRBCs) and produced E rosette formation. Cytofluorography using monoclonal antibodies demonstrated the B cell nature of these cells and the absence of the SRBC receptor. Further documentation that the binding of SRBCs was mediated through immunologic reaction included E rosette formation inhibition by monospecific antisera and hemagglutination of SRBCs by a paraprotein isolated from the patient's serum. Fusion of the CLL cells with a human hypoxanthine-aminopterin- thymidine-sensitive plasma cell line resulted in the production of human hybridomas that secreted the SRBC-reactive IgM antibody. An analysis of clinical histories of CLL patients whose cells exhibited this phenomenon from both immunologic and clinical perspectives is presented.

Monoclonal B lymphocytes with the characteristics of “indolent” chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts

Blood ◽  
2002 ◽  
Vol 100 (2) ◽  
pp. 635-639 ◽  
Author(s):  
Andy C. Rawstron ◽  
Michael J. Green ◽  
Anita Kuzmicki ◽  
Ben Kennedy ◽  
James A. L. Fenton ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
B Lymphocytes ◽  
Malignant Disease ◽  
Early Stage ◽  
Flow Cytometric Analysis ◽  
Lymphocytic Leukemia ◽  
Clinical Disease ◽  
Healthy Individuals ◽  
Color Flow ◽  
Female Ratio

Abstract Molecular and cellular markers associated with malignant disease are frequently identified in healthy individuals. The relationship between these markers and clinical disease is not clear, except where a neoplastic cell population can be identified as in myeloma/monoclonal gammopathies of undetermined significance (MGUS). We have used the distinctive phenotype of chronic lymphocytic leukemia (CLL) cells to determine whether low levels of these cells can be identified in individuals with normal complete blood counts. CLL cells were identified by 4-color flow cytometric analysis of CD19/CD5/CD79b/CD20 expression in 910 outpatients over 40 years old. These outpatients were age- and sex-matched to the general population with normal hematologic parameters and no evident history of malignant disease. CLL phenotype cells were detectable in 3.5% of individuals at low level (median, 0.013; range, 0.002- 1.458 × 109 cells/L), and represented a minority of B lymphocytes (median, 11%; range, 3%-95%). Monoclonality was demonstrated by immunoglobulin light-chain restriction in all cases with CLL phenotype cells present and confirmed in a subset of cases by consensus-primer IgH-polymerase chain reaction. As in clinical disease, CLL phenotype cells were detected with a higher frequency in men (male-to-female ratio, 1.9:1) and elderly individuals (2.1% of 40- to 59-year-olds versus 5.0% of 60- to 89-year-olds, P = .01). The neoplastic cells were identical to good-prognosis CLL, being CD5+23+20wk79bwk11a−22wksIgwkCD38−, and where assessed had a high degree (4.8%-6.6%) of IgH somatic hypermutation. The monoclonal CLL phenotype cells present in otherwise healthy individuals may represent a very early stage of indolent CLL and should be useful in elucidating the mechanisms of leukemogenesis.

scholarly journals HuR Affects Proliferation and Apoptosis of Chronic Lymphocytic Leukemia Cells via NF-κB Pathway

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Kai Xiao ◽  
Lin Yang ◽  
Xinfeng Gao ◽  
Ying An ◽  
Wei Xie ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
B Lymphocytes ◽  
Caspase 3 ◽  
Human Tumor ◽  
Lymphocytic Leukemia ◽  
Cell Counting ◽  
Cell Sensitivity ◽  
Proliferation And Apoptosis ◽  
Potential Strategy ◽  
The Relationship

Objective. To investigate the effects of HuR protein on the treatment of chronic lymphocytic leukemia (CLL). Methods. LCL lymphoblast cells and B lymphocytes were subjected to HuR overexpression (OV) or interference (IV). Western blot was used to observe the protein expression of human tumor necrosis factor-associated factor 1 (TRAF1), human inhibitor of nuclear factor kappa-B kinase α (IKK-α), NF-κB-inducing kinase (NIK), and p52. Flow cytometry was performed to evaluate apoptosis, and the mRNA expression of TRAF1 was examined by quantitative reverse transcription polymerase chain reaction. Immunofluorescence was carried out to visualize the expression of HuR, and the relationship between HuR and TRAF1 was observed by pull-down test. Cell sensitivity to chlorambucil (CLB) and fludarabine (Flu) was assessed by Cell Counting Kit-8. Results. The expression of HuR and TRAF1 in LCLs was significantly increased compared to that in B lymphocytes. Compared with the control, HuR OV significantly increased the expression of TRAF1 (P<0.05), whereas it was significantly decreased in the IV group (P<0.05). HuR can bind to TRAF1 directly, and the binding rate is positively correlated with HuR expression. After inhibiting HuR, the expression of TRAF1, IKK-α, NIK, p52, pro-Caspase 3, and PARP was significantly upregulated in LCLs and B lymphocytes (P<0.05), while Caspase 3 was downregulated (P<0.05). Compared with the control, the proliferation of LCLs and B lymphocytes treated by CLB and Flu decreased significantly after HuR blockade (P<0.05). Conclusion. HuR may be a key protein regulating CLL resistance. After inhibiting HuR, inflammatory response and apoptosis were significantly increased, and the cell sensitivity to CLB and Flu increased, suggesting that inhibiting HuR activity may be a potential strategy to solve the problem of drug resistance in CLL cells.

Sign in / Sign up

Export Citation Format

Share Document